Published in Acad Radiol on December 01, 2006
Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: a multicenter study. World J Gastroenterol (2009) 2.36
Role of sonoelastography in non-palpable breast lesions. Eur Radiol (2008) 1.36
Ultrasonic viscoelasticity imaging of nonpalpable breast tumors: preliminary results. Acad Radiol (2008) 1.16
Harmonic Motion Imaging (HMI) for Tumor Imaging and Treatment Monitoring. Curr Med Imaging Rev (2012) 0.86
Local and regional staging of invasive breast cancer with sonography: 25 years of practice at MD Anderson Cancer Center. Oncologist (2013) 0.86
Stiffness of the surrounding tissue of breast lesions evaluated by ultrasound elastography. Eur Radiol (2014) 0.86
Predictors of interobserver agreement in breast imaging using the Breast Imaging Reporting and Data System. Breast Cancer Res Treat (2010) 0.85
Differential diagnosis of breast lesions using ultrasound elastography. Indian J Radiol Imaging (2011) 0.84
Elastography ultrasound for breast lesions: fat-to-lesion strain ratio vs gland-to-lesion strain ratio. Eur Radiol (2014) 0.84
Endoscopic ultrasound: Elastographic lymph node evaluation. Endosc Ultrasound (2015) 0.83
Fractional derivative models for ultrasonic characterization of polymer and breast tissue viscoelasticity. IEEE Trans Ultrason Ferroelectr Freq Control (2009) 0.81
Correlation between semiquantitative sonoelastography and immunohistochemistry in the evaluation of testicular focal lesions. Cancer Imaging (2014) 0.80
TSI ultrasound elastography for the diagnosis of chronic allograft nephropathy in kidney transplanted patients. J Ultrason (2013) 0.76
The Role of Ultrasographic Elastography in the Differential Diagnosis of Breast Masses and Its Contribution to Classical Ultrasonographic Evaluation. J Breast Health (2013) (2014) 0.75
Ultrasonic Elastography Research Based on a Multicenter Study: Adding Strain Ratio after 5-Point Scoring Evaluation or Not. PLoS One (2016) 0.75
The Added Value of Color Parameters in Analyzing Elastographic Images of Ultrasound Detected Breast Focal Lesions. Clujul Med (2015) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Prevention of intraoperative hypothermia in neonates and infants: results of a prospective multicenter observational study with a new forced-air warming system with increased warm air flow. Paediatr Anaesth (2013) 2.73
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation (2008) 2.41
A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum (2005) 2.36
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
FLT3 as a therapeutic target in AML: still challenging after all these years. Blood (2010) 2.25
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology (2004) 2.16
Noninvasive detection of coronary artery stenoses with multislice computed tomography or magnetic resonance imaging. Ann Intern Med (2006) 2.04
Head-to-head comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard. J Am Coll Cardiol (2012) 1.90
Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer (2009) 1.89
Assessment of unspecific near-infrared dyes in laser-induced fluorescence imaging of experimental arthritis. Acad Radiol (2006) 1.80
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Rheumatoid arthritis of the shoulder joint: comparison of conventional radiography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.79
Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 1.79
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood (2009) 1.70
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69
Significant differentiation of focal breast lesions: calculation of strain ratio in breast sonoelastography. Acad Radiol (2010) 1.62
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2011) 1.59
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood (2009) 1.58
Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology (2006) 1.57
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Does ultra-low-dose CT with a radiation dose equivalent to that of KUB suffice to detect renal and ureteral calculi? J Comput Assist Tomogr (2005) 1.54
Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol (2003) 1.53
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood (2008) 1.51
Comparison of non-gated vs. electrocardiogram-gated 64-detector-row computed tomography for integrated electroanatomic mapping in patients undergoing pulmonary vein isolation. Europace (2010) 1.50
Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging (2008) 1.48
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46
Determinants and patient-reported long-term outcomes of physician empathy in oncology: a structural equation modelling approach. Patient Educ Couns (2007) 1.46
Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology (2010) 1.45
Triage of patients with suspected coronary artery disease using multislice computed tomography. Acad Radiol (2007) 1.41
Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer. Onkologie (2012) 1.40
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol (2010) 1.39
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
Chronic myelogenous leukemia molecular signature. Oncogene (2003) 1.31
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer (2007) 1.29
Anaerobic degradation of n-hexane in a denitrifying bacterium: further degradation of the initial intermediate (1-methylpentyl)succinate via C-skeleton rearrangement. Arch Microbiol (2001) 1.28
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol (2009) 1.28
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol (2015) 1.26
Multisegment and halfscan reconstruction of 16-slice computed tomography for detection of coronary artery stenoses. Invest Radiol (2004) 1.26
Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology (2002) 1.19
Cost effectiveness of coronary angiography and calcium scoring using CT and stress MRI for diagnosis of coronary artery disease. Eur Radiol (2006) 1.19
Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology (2002) 1.18
Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol (2004) 1.18
Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging (2011) 1.18
Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomedicine (2013) 1.17
Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol (2002) 1.17
Cardiac magnetic resonance elastography. Initial results. Invest Radiol (2008) 1.17
Evaluation of global and regional left ventricular function with 16-slice computed tomography, biplane cineventriculography, and two-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging. J Am Coll Cardiol (2006) 1.17
Spinal changes in patients with spondyloarthritis: comparison of MR imaging and radiographic appearances. Radiographics (2005) 1.16
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer (2013) 1.16
Diffusion-weighted echo-planar magnetic resonance imaging for the assessment of tumor cellularity in patients with soft-tissue sarcomas. J Magn Reson Imaging (2009) 1.13
Cardiac MR elastography: comparison with left ventricular pressure measurement. J Cardiovasc Magn Reson (2009) 1.13
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol (2010) 1.12
Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol (2014) 1.12
Computed tomography for preoperative planning in minimal-invasive total hip arthroplasty: radiation exposure and cost analysis. Eur J Radiol (2009) 1.12
Anaerobic degradation of ethylbenzene by a new type of marine sulfate-reducing bacterium. Appl Environ Microbiol (2003) 1.11
Digital mammography using iodine-based contrast media: initial clinical experience with dynamic contrast medium enhancement. Invest Radiol (2005) 1.10
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol (2005) 1.09
Real-time sonoelastography of the cervix: tissue elasticity of the normal and abnormal cervix. Acad Radiol (2007) 1.09
Magnetic resonance imaging of active sacroiliitis: do we really need gadolinium? Eur J Radiol (2009) 1.08
Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate. Invest Radiol (2014) 1.08
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer (2008) 1.06
Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos (2014) 1.06
Epidural venous enlargements presenting with intractable lower back pain and sciatica in a patient with absence of the infrarenal inferior vena cava and bilateral deep venous thrombosis. Spine (Phila Pa 1976) (2007) 1.06
Non-cardiac findings on coronary computed tomography and magnetic resonance imaging. Eur Radiol (2007) 1.06
Low-dose CT of the paranasal sinuses with eye lens protection: effect on image quality and radiation dose. Eur Radiol (2002) 1.06
The effect of prior exposure to imatinib on transplant-related mortality. Haematologica (2006) 1.05
Near-infrared laser computed tomography of the breast first clinical experience. Acad Radiol (2008) 1.04
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis (2012) 1.04
Magnetic resonance imaging of the upper abdomen using a free-breathing T2-weighted turbo spin echo sequence with navigator triggered prospective acquisition correction. J Magn Reson Imaging (2005) 1.03
Evaluation of contrast-enhanced digital mammography. Eur J Radiol (2009) 1.02
Underfinancing of 90.3% for implant costs of prostheses and expanders in DRG revenues for uni- and bilateral mastectomy with immediate breast reconstruction. Onkologie (2010) 1.01
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol (2008) 1.01
Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer (2007) 1.01
Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer. FASEB J (2007) 1.01
Influence of heart rate on diagnostic accuracy and image quality of 16-slice CT coronary angiography: comparison of multisegment and halfscan reconstruction approaches. Eur Radiol (2007) 1.00
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol (2012) 0.99